|
Re: Biogen/Eisai Scrap Aducanumab
|
3
|
Resverlogix Corp.
|
Mar 23, 2019 10:10AM
|
|
A couple recent epigenetic/bromodoma... reviews from 2018
|
3
|
Resverlogix Corp.
|
Apr 16, 2019 11:00AM
|
|
Re: Resverlogix presentation at European Meeting on Complement in Human Disease meeting
|
3
|
Resverlogix Corp.
|
Sep 08, 2017 06:43PM
|
|
Re: Great Presetation today
|
3
|
Zenith Epigenetics
|
Oct 19, 2017 09:40AM
|
|
Wednesday 3/23/16
|
3
|
Resverlogix Corp.
|
Mar 18, 2016 08:49AM
|
|
Re: NASH is a $35 Billion US/year market
|
3
|
Resverlogix Corp.
|
Jan 02, 2019 11:04AM
|
|
Re: Final draft of SA post...
|
3
|
Resverlogix Corp.
|
Mar 26, 2019 10:34PM
|
|
Re: RBC unregistered to registered account
|
3
|
Zenith Epigenetics
|
Apr 01, 2019 08:11PM
|
|
Re: What if RRR MACE is significant at 90% confidence?
|
3
|
Resverlogix Corp.
|
Apr 24, 2018 11:13AM
|
|
Re: 2019 Potential Events
|
3
|
Resverlogix Corp.
|
Jan 02, 2019 11:23AM
|
|
NEJM Editorial on REDUCE-IT
|
3
|
Resverlogix Corp.
|
Nov 16, 2018 12:29PM
|
|
Re: Phase 3 - Fall Start
|
3
|
Resverlogix Corp.
|
Jun 22, 2015 11:26AM
|
|
Re: Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for COVID-19
|
3
|
Resverlogix Corp.
|
Apr 12, 2021 10:54AM
|
|
Re: New Interim Financials and MD&A docs on SEDAR
|
3
|
Resverlogix Corp.
|
Dec 16, 2015 12:42PM
|
|
RVX Presenting at Roth today
|
3
|
Resverlogix Corp.
|
Mar 15, 2016 11:38AM
|
|
Re: Patient Enrollment Modeling
|
3
|
Resverlogix Corp.
|
Dec 01, 2018 08:33PM
|
|
Re: What value will be given Apabetalone for CD,...
|
3
|
Resverlogix Corp.
|
Nov 24, 2019 10:43PM
|
|
Re: BET bromodomain protein inhibitors and AML
|
3
|
Zenith Epigenetics
|
Aug 30, 2017 05:08PM
|
|
Resverlogix Provides Update on BETonMACE Phase 3 Epigenetics Trial
|
3
|
Resverlogix Corp.
|
Jun 12, 2019 10:56AM
|
|
Re: (one) case study
|
3
|
Zenith Epigenetics
|
Sep 04, 2018 07:54PM
|
